Article
Gastroenterology & Hepatology
Brigida Barberio, Lesley A. Houghton, Yan Yiannakou, Edoardo Savarino, Christopher J. Black, Alexander C. Ford
Summary: The study found that among individuals self-identifying as having IBS, the diagnosis and subtype of IBS were less stable, and starting new treatments did not affect symptom stability.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Gastroenterology & Hepatology
Vivek C. Goodoory, Lesley A. Houghton, Yan Yiannakou, Christopher J. Black, Alexander C. Ford
Summary: This study found that the natural history of irritable bowel syndrome (IBS) defined according to the Rome IV criteria is more severe compared to IBS defined by the Rome III criteria. Approximately 60% of the participants met the Rome IV criteria, while approximately 40% met the Rome III criteria. Individuals with Rome IV IBS were more likely to seek medical care, start new treatments, and have more treatment cycles compared to those with Rome III IBS. Additionally, Rome IV IBS patients had more severe symptoms, greater impact on daily activities, and poorer psychological health.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford
Summary: The study suggests that diagnosing IBS according to the Rome IV criteria and conducting limited investigation is safe and durable. Among IBS patients, although 1 in 6 were referred again due to gastrointestinal symptoms, missed organic gastrointestinal disease occurred in only 1% of patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Microbiology
Tarek Mazzawi
Summary: Research suggests that manipulating gut microbiota can improve symptoms of irritable bowel syndrome (IBS), with dietary management and other approaches showing promise in changing gut composition and alleviating IBS symptoms. However, more research is needed to identify the exact mixture of beneficial bacteria.
Review
Immunology
Lin Xiao, Qin Liu, Mei Luo, Lishou Xiong
Summary: Research has identified the significant roles that microbiota-derived metabolites play in the development of IBS symptoms in patients, shedding light on the complex interplay between gut microbiota and IBS.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Brigida Barberio, Yan Yiannakou, Lesley A. Houghton, Christopher J. Black, Edoardo Savarino, Alexander C. Ford
Summary: In a longitudinal study, individuals with overlapping symptoms of IBS and FD were found to have more severe conditions, higher rates of seeking medical help, and greater psychological health issues compared to those with IBS alone.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Qi Su, Hein M. Tun, Qin Liu, Yun Kit Yeoh, Joyce Wing Yan Mak, Francis K. L. Chan, Siew C. Ng
Summary: This study examined the association between gut microbiota and Irritable bowel syndrome (IBS) subtypes, and found that there are distinct differences in microbiota composition among different IBS subtypes. The microbial diversity is significantly reduced in IBS-D and IBS-U, but not in IBS-C. The study also identified microbial signatures associated with depression in IBS patients. Factors such as gender, age, and dietary patterns have significant effects on gut microbiota in different IBS subtypes. These findings emphasize the importance of personalized gut microbiome modulation approaches for optimal therapeutic effects in different subtypes of IBS.
Article
Gastroenterology & Hepatology
Vivek C. Goodoory, Cho Ee Ng, Christopher J. Black, Alexander C. Ford
Summary: This study provides contemporary estimates of direct healthcare costs of IBS in the UK, finding that individuals with opiate use, more severe symptoms, shorter duration of IBS, lower quality of life, and higher levels of depression require higher healthcare costs.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Laurie Keefer, Sarah K. Ballou, Douglas A. Drossman, Gisela Ringstrom, Sigrid Elsenbruch, Brjann Ljotsson
Summary: This report summarizes the consensus and methods of an international expert team regarding the use of behavioral interventions in patients with DGBIs. By reviewing existing scientific literature, the committee confirmed the definition and evidence of BGBT, connecting it with DGBI-specific behavioral targets and techniques to support clinical decision-making in providing BGBT.
Review
Gastroenterology & Hepatology
Brennan Spiegel
Summary: This article proposes a hypothesis, known as the gravity hypothesis, that seeks to explain the pathogenesis of irritable bowel syndrome (IBS) by relating it to the influence of gravity on human evolution. It suggests that ineffective gravity management systems may lead to the development of IBS. The article reviews the impact of gravity on human evolution, discusses the imperfect adaptation of Homo sapiens to gravity, and explores the consequences of gravity intolerance in relation to IBS. It also considers the diagnostic and therapeutic implications of this hypothesis and suggests further experiments to support or reject it.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Microbiology
Yu Gu, Lingfeng Li, Min Yang, Tianyu Liu, Xueli Song, Xiali Qin, Xin Xu, Jinghua Liu, Bangmao Wang, Hailong Cao
Summary: This article discusses the complex relationship between bile acids and gut microbiota in the pathogenesis of irritable bowel syndrome (IBS), as well as the possible molecular mechanisms and biomarkers. In addition, it evaluates therapeutic strategies for IBS that regulate the bile acid-gut microbiota axis. These studies provide new insights into the treatment of IBS.
CRITICAL REVIEWS IN MICROBIOLOGY
(2023)
Review
Food Science & Technology
Ao Liu, Wenkang Gao, Yixin Zhu, Xiaohua Hou, Huikuan Chu
Summary: Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder that significantly affects personal health and imposes a substantial economic burden on society. Emerging evidence suggests that IBS is associated with gut microbial dysbiosis, including not only bacteria but also fungi, viruses, archaea, and other parasitic microorganisms. Fungi and methanogens play a role in diagnosis and treatment of IBS.
Review
Gastroenterology & Hepatology
Eline Margrete Randulff Hillestad, Aina van der Meeren, Bharat Halandur Nagaraja, Ben Rene Bjorsvik, Noman Haleem, Alfonso Benitez-Paez, Yolanda Sanz, Trygve Hausken, Guelen Arslan Lied, Arvid Lundervold, Birgitte Berentsen
Summary: This comprehensive review discusses the major features of irritable bowel syndrome and its interaction with gut microbiota, clinical microbiota-altering treatments such as low FODMAP diet and fecal microbiota transplantation, neuroimaging and microbiota analysis methods, and current and future challenges in big data analysis in IBS.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Medicine, General & Internal
Sofia D. Shaikh, Natalie Sun, Andrew Canakis, William Y. Park, Horst Christian Weber
Summary: Irritable Bowel Syndrome (IBS) is a functional disorder of the gastrointestinal tract characterized by abdominal pain and altered bowel habits. It has a high prevalence and disease burden, affecting the quality of life, work productivity and healthcare utilization and costs. IBS is associated with various conditions, including psychiatric comorbidities. The pathophysiology involves dysregulation of the brain-gut axis, leading to changes in intestinal motility, gut permeability, visceral hypersensitivity and gut microbiota composition. This article aims to explore the role of gut microbiota in the pathophysiology of IBS, factors influencing the gut microbiome, and the potential of microbiome as a treatment target.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cell Biology
Hadar Bootz-Maoz, Ayelet Pearl, Ehud Melzer, Stephen Malnick, Efrat Sharon, Yifat Bennet, Rotem Tsentsarevsky, Shlomi Abuchatzera, Sivan Amidror, Elana Aretz, Shalhevet Azriel, Chen Gam Ze Letova, Maria Naama, Irit Shoval, Orly Yaron, Sarit Karako-Lampert, Shai Bel, Nissan Yissachar
Summary: Changes in microbiome composition are associated with human diseases, and finding causative connections between specific microbial taxa and their impact on the host tissues is crucial for clinical translation. This study infuses gut organ cultures with microbiota samples from therapy-naive patients with IBS under a low-FODMAP diet and identifies a diet-sensitive pathobiont that disrupts gut barrier functions. The findings support the potential feasibility of microbiome-based therapies in IBS.